Compare Amgen, Inc. (AMGN) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Oklo Inc — how do they compare? Amgen, Inc. trades at $417.45 (market cap $224.14B), while Oklo Inc trades at $45.29 (market cap $8.74B). The key difference: Amgen, Inc. is far larger — about 25.6× Oklo Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| AMGN | OKLO | |
|---|---|---|
Market Cap | $224.14B | $8.74B |
Sector | Health | Technology |
52-Week High | $417.20 | $174.14 |
52-Week Low | $271.18 | $36.84 |
Enterprise Value | $267.45B | $6.28B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
OKLO trades at $45.71, up 2.74% with a bullish technical outlook despite recent volatility. The company reported its first revenue of $1.2 million in Q2 2026 but continues to post significant losses (-$105.66M net income in 2025) with negative margins. Analyst consensus remains strongly bullish with a $77.07 price target, though CEO share sales and high cash burn present near-term concerns.
While OKLO shows promising nuclear technology development with recent milestones, investors face substantial execution risks amid widening losses and negative cash flow. The stock offers high growth potential in the emerging nuclear energy sector but requires careful risk management given the pre-profitability stage and volatile price action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
